Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes

AIM: To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist, in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Two randomized, double‐blind, placebo‐controlled phase 2 trials were condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Kun‐Ho, Kang, Jahoon, Kwon, Se Chang, Trautmann, Michael E., Hompesch, Marcus, Stewart, John, Sorli, Christopher H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383501/
https://www.ncbi.nlm.nih.gov/pubmed/32175655
http://dx.doi.org/10.1111/dom.14032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383501/
https://www.ncbi.nlm.nih.gov/pubmed/32175655
http://dx.doi.org/10.1111/dom.14032

Ejemplares similares